Sign up to save your podcasts
Or
Share Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives
Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.
Credit available for this activity expires: 6/15/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532
View all episodes
By Medscape Podcasts
4
77 ratings
Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.
Credit available for this activity expires: 6/15/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532
More shows like Keeping Current
View all
JAMA Editors' Summary
131 Listeners
The Bob Harrington Show
13 Listeners
NEJM This Week
323 Listeners
This Week in Cardiology
866 Listeners
JAMA Clinical Reviews
492 Listeners
AFP: American Family Physician Podcast
695 Listeners
One-on-One with Eric Topol
18 Listeners
Mayo Clinic Talks
276 Listeners
Frankly Speaking About Family Medicine
252 Listeners
The Curbsiders Internal Medicine Podcast
3,318 Listeners
Emergency Medical Minute
258 Listeners
JAMA Medical News
87 Listeners
Core IM | Internal Medicine Podcast
1,087 Listeners
Annals On Call Podcast
186 Listeners
The Clinical Problem Solvers
514 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
348 Listeners
Medicine and the Machine
59 Listeners
Keeping Current CME
25 Listeners
Ninja Nerd
286 Listeners